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Abstract
Background: The heterogeneity and tumourigenicity of metastatic melanoma is attributed to a cancer stem cell
model, with CD133 considered to be a cancer stem cell marker in melanoma as well as other tumours, but its role
has remained controversial.
Methods: We iteratively sorted CD133+ and CD133- cells from 3 metastatic melanoma cell lines, and observed
tumourigenicity and phenotypic characteristics over 7 generations of serial xeno-transplantation in NOD/SCID mice.
Results: We demonstrate that iterative sorting is required to make highly pure populations of CD133+ and
CD133- cells from metastatic melanoma, and that these two populations have distinct characteristics not
related to the cancer stem cell phenotype. In vitro, gene set enrichment analysis indicated CD133+ cells were
related to a proliferative phenotype, whereas CD133- cells were of an invasive phenotype. However, in vivo,
serial transplantation of CD133+ and CD133- tumours over 7 generations showed that both populations were
equally able to initiate and propagate tumours. Despite this, both populations remained phenotypically
distinct, with CD133- cells only able to express CD133 in vivo and not in vitro. Loss of CD133 from the
surface of a CD133+ cell was observed in vitro and in vivo, however CD133- cells derived from CD133+
retained the CD133+ phenotype, even in the presence of signals from the tumour microenvironment.
Conclusion: We show for the first time the necessity of iterative sorting to isolate pure marker-positive and
marker-negative populations for comparative studies, and present evidence that despite CD133+ and CD133-
cells being equally tumourigenic, they display distinct phenotypic differences, suggesting CD133 may define a
distinct lineage in melanoma.
Background
The heterogeneity and tumourigenicity of metastatic
melanoma has been widely debated. Originally attrib-
uted to a stochastic model of clonal evolution [1], in re-
cent years it has been proposed to follow a cancer stem
cell model [2–6]. This model suggests tumour initi-
ation, growth and recurrence is driven by a sub-
population of tumourigenic cells that undergo stem
cell-like asymmetric division to self-renew and produce
hierarchical lineages of phenotypically differentiated,
non-tumourigenic cells. However, the evidence that
melanoma follows a cancer stem cell model is disputed
[7–10]. Variations in methodology, from the reliability
of xenografting melanoma cells taken directly from the
patient, to how immuno-compromised mice need to be
to accurately assess tumourigenicity, have raised doubts
of the validity of a cancer stem cell model for melan-
oma [11, 12].
Key evidence supporting a melanoma cancer stem
cell model has come from isolating cells that differ-
entially express stem and progenitor cell markers, or
chemo-resistance markers, and comparing their tumouri-
genic ability. In the case of melanoma, cells expressing the
surface markers CD133 [4, 13] and ABCG2 [4], ABCB5
[14] and CD271 [15–17] have been examined, as well as
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the intracellular enzyme Aldehyde Dehydrogenase [18].
These studies claim there is a distinct lineage of mel-
anoma stem cells, with marker-positive cells having
greater tumourigenicity than marker-negative cells,
and that only marker-positive cells have the ability to
recapitulate the phenotypic heterogeneity of parental
tumours [14].
In contrast, a study of 22 heterogeneously expressed
markers from stage II, III and IV patient melanomas,
including CD271, ABCB5, [7] and CD133 [8] reported
that all cells, whether marker-positive or -negative, had
tumourigenic capacity when assayed in highly immune-
deficient hosts. In addition, tumours derived from both –
positive and -negative cells recapitulated the complete
spectrum of marker expression observed in the original
tumour. These data implied that surface marker expres-
sion is reversible and does not mark any particular lineage.
Instead, phenotype switching occurs in melanoma, with
tumourigenicity driven by microenvironment switches
from a proliferative to an invasive phenotype [19–22].
Other studies examining lineage and tumourigenicity have
been similarly conflicted. Roesch et al. defined a slow-
cycling lineage of JARID1B-positive cells as essential for
continuous tumour growth [6], whereas Held et al.
demonstrated multiple distinct populations with varying
tumourigenic ability after single-cell engraftment of CD34
and CD271 subsets [17].
To investigate the relationship between cancer stem
cells, tumourigenicity and surface marker expression,
we studied the cell surface marker CD133 in primary
melanoma cell lines. CD133 has been shown to be in
part co-expressed with ABCB5 and CD271 [23–27], and
has been used as a stem cell and cancer stem cell marker
in melanoma [4, 28, 29], glioblastoma [30], colorectal can-
cer [31, 32] and others. While stressors such as hypoxia,
chemotherapy and metabolic defects induce CD133 ex-
pression, the role in tumourigenesis is still not understood.
CD133+ and CD133- cells were sorted from 3 pri-
mary melanoma cell lines, and tumourigenicity and
phenotypic characteristics observed over 7 generations
of serial xeno-transplantation in NOD/SCID mice. We
show for the first time the necessity of iterative sorting
to isolate pure marker-positive and marker-negative
populations for comparative studies of marker-positive
cells in tumours, and present evidence that despite
CD133+ and CD133- cells being equally tumourigenic,
CD133 defines two phenotypically distinct populations
in metastatic melanoma.
Methods
Cells and cell Culture
This study utilized seven human melanoma cells lines
(<15 passage) previously established from Stage IV
malignant melanoma [33]. Ethical approval to use these
cell lines for research purposes has been granted by the
Austin Health Human Research Ethics Committee. All 7
lines were used in the GEO and GSEA studies (Fig. 1b
and c), with LM-MEL-15, LM-MEL-34, and LM-MEL-
62 (established from metastatic lymph node axilla), used
in all other experiments, unless otherwise stated. LM-
MEL cell lines were cultured in RPMI-1640 medium
supplemented with 10 % fetal bovine serum (Sigma-Al-
drich, Auckland, NZ), 100 units/mL penicillin, 100 μg/
mL streptomycin, 0.1 % mercaptoethanol, 2 mM gluta-
max, and 25 mM HEPES. All plasticware was obtained
from Thermo Scientific, NZ and all cell culture reagents
from Invitrogen (Auckland, New Zealand).
Magnetic-Activated Cell Sorting (MACS) for GEO and
GSEA Studies
Cells were separated into CD133+ and CD133- popula-
tions using magnetic beads according to the manufac-
turers protocol (Miltenyi Biotec, Bergisch Gladbach,
Germany) as described previously [34]. Briefly, LS
columns were used for positive selection followed by
depletion with LD columns. Columns were run in serial
to enhance purity. Sorting results were tested for purity
by flow cytometry.
Gene Expression Omnibus (GEO)
RNA from CD133+ and CD133- cells was hybridized
to Affymetrix U133A gene chips following standard
Affymetrix protocols at the Memorial Sloan-Kettering
Cancer Center Genomics Core Laboratory. For deter-
mination of stem cell signatures, gene expression data
was downloaded from the National Center for Biotech-
nology Information GEO database and each sample
rank-transformed. The expression of each pathway was
scored by a modified, one-sided Kolmogorov–Smirnov
statistic - based on the GSEA algorithm applied to sin-
gle samples. The transformation was such that the null
distribution, N(0,1), was determined from the cumula-
tive distribution function of the background distribu-
tion score (10,000 gene name permutations). For each
pathway the resulting normalized score was standard-
ized against all samples of the same platform found in
GEO using the ternary representation -1 and +1 for the
top and bottom, 15 % and 0 otherwise.
Gene Set Enrichment Analysis (GSEA)
RNA samples from cells sorted based on CD133
expression using MACS were analyzed on Affymetrix
HG-U133A microarrays at the Memorial Sloan-Kettering
Cancer Centre Genomics Core Laboratory. Raw data were
normalized using the Robust Multiarray Average (RMA)
method [35]. Gene Set Enrichment Analysis [36] was
performed using the RMA normalized data to calculate
the Enrichment Score (ES), with gene set permutation and
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a 5 % False Discovery Rate cutoff. A nominal p value was
used to estimate the statistical significance of the ES (*,
P < 0.05, **, P <0.01, ***, P < 0.001.). Gene sets included
those curated in category C2 of the MSigDB database
v3.0, as well as additional melanoma and cancer-
related gene lists derived from recent publications. Full
GSEA data available in Supporting Information.
Flow Cytometry and Fluorescence-Activated Cell Sorting
(FACs) for xenotransplantation
Cells, suspended in HBSS at 2 × 106 cells/mL, were incu-
bated in the dark for 30 mins at room temperature with
1:100 dilution of AC133, 293C, or the appropriate mouse
IgG1 or mouse IgG2b isotype control antibodies, all
directly conjugated to R-PE (Miltenyi Biotech, Germany).
Fig. 1 CD133+ and CD133- are not stem-like but display distinct phenotypes. a CD133 cell surface expression quantified by flow
cytometry in 3 human primary lines derived from Stage IV melanoma metastases (LM-MEL-15, LM-MEL-34, LM-MEL-62). CD133 mRNA
expression measured by real-time RT-PCR. Average of 3 replicate experiments +/- standard error. b Gene-expression profile for CD133+
(right bars, green) and CD133- (left bars, red) from 7 human primary malignant melanoma lines, using Gene Set Enrichment Analyses
(GSEA) with a 5 % False Discovery Rate cut-off. Selected gene sets shown, with gene set size given in parentheses. Shading shows
percentage of genes contributing to Enrichment Score: hatching, 20–50 %; grey, 50–75 %; black, 75–100 %. Nominal P values: *, P < 0.05,
**, P <0.01, ***, P < 0.001. c Distribution pattern of CD133+ (green) and CD133- (red) microarray gene expression profiles compared to
human Embryonic Stem (hES), induced Pluripotency Stem (iPS) cells (black), and fibroblasts and melanocytes (blue). Grey depicts global
distribution of gene arrays in the Gene Expression Omnibus (GEO) database
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Cells were washed then analyzed on a BD FACSort
(Becton Dickson, CA) using propidium iodide as a via-
bility dye. CD133 expression on viable cells was ana-
lyzed with FlowJo software (TreeStar, CA). For sorting
experiments, cells were sorted at 20 psi sheath pres-
sure, with a 100 μm nozzle. Sort gates were set at the
top and bottom 5 % of viable CD133-PE histogram.
Mice
Breeding pairs of the inbred strain NOD/SCID were ob-
tained from the Hercus-Taieri Research Unit, University
of Otago, New Zealand. All mice were maintained at the
Biomedical Research Unit of the Malaghan Institute
of Medical Research. Experimental protocols were
approved by Victoria University Animal Ethics Com-
mittee, Wellington, New Zealand, and performed ac-
cording to institutional guidelines. Mice were 6 to
12 weeks of age.
Tumour preparation and serial transplant
2 × 105 cells were suspended in 50 μL of Geltrex (Invitro-
gen, Auckland NZ) and injected sub-cutaneously into
NOD/SCID mice, 3–5 mice per group. Tumour growth
was recorded at 3–6 days, and when ~200 mm3, mice
were culled by cervical dislocation and tumours excised.
Tumours from each animal in the group were pooled,
mechanically dissociated and filtered through 100, 70 and
40 μm filters into a single cell suspension, then plated into
tissue culture plates in 20 mL of cell culture media. The
following day, media was replaced, leaving adherent
melanoma cells. Cultures were expanded by passage as
required. Cells were lifted with 0.05 % Trypsin-EDTA (Life
Technologies, NZ), and washed 3 times before being
resuspended in Geltrex for the next injection.
Statistical analysis
Basic statistical analyses of tumour growth and CD133+
cell number (mean and standard error) were carried out
using the appropriate packages in Excel (Microsoft) or
Prism (Graphpad). More complex statistical analyses of
cell surface CD133+ cell numbers or CD133 transcript
could not be performed due to limited size of datasets.
Statistical significance of GSEA data was determined
using standard parameters [36].
RNA extraction and Real Time-PCR
RNA from freshly excised pooled tumours, or from cells
in culture, was extracted using a RNeasy kit (QIAGEN,
Valenica, CA). cDNA was synthesized using I-Script c-
DNA Synthesis (BioRad, Auckland, NZ). Real-time PCR
was performed using primers to 18 s (QT00199367) and
CD133 (QT00075586), with QuantiTect SYBR Green
PCR Master Mix (QIAGEN, Valenica, CA) in the 7500
Real Time PCR System (Applied Biosystems, Carlsbad,
CA), according to manufacturer’s instructions. Cycle
threshold (Ct) for CD133 was normalized to 18 s rRNA
Ct (ΔCT). ΔCT was normalized between the vehicle and
treated cell RNA (ΔΔCt). Amplification efficiency of all
primers were equivalent so fold change was determined
by 2-ΔΔCt. The CD133 primers amplified exons 5, 6 and
7, and detected all known mRNA variants. Caco-2 cells
were used as a positive control for CD133 expression.
Immunohistochemistry
Following dewaxing, 4 mm paraffin sections of tu-
mours were dehydrated in graded ethanol, endogen-
ous peroxidase activity blocked for 10 min in 3 %
hydrogen peroxide, and antigens retrieved by micro-
wave boiling in 10 mM citrate buffer pH 6 (cat. no.
TA-050-CBX, Thermo Fisher) followed by 20 min
cooling. Sections were incubated for 45 min at room
temperature in 1:700 mouse-anti-human-CD133 anti-
body (ahE2, mAb80B258, kindly provided by Dr Denis
Corbeil, Max-Planck-Institute of Molecular Cell Biol-
ogy and Genetics, Dresden, Germany). mIgG1 (X0931,
DAKO) of matching concentration served as negative
control. Binding was detected with anti-mouse-HRP
polymer (cat. No. K4004, Envision™+, DAKO, 1 h, room
temperature), and visualized with AEC. Nuclei were coun-
terstained with Mayer’s Hemotoxylin (7 s). Slides were
mounted with crystal mount and subsequently cover
slipped with Pertex.
Image analysis
IHC images were analysed using Aperio slide viewer
(http://www.aperio.com).
Results
CD133+ and CD133- melanoma cells have distinct
phenotypes
This study utilized human malignant melanoma cells lines
(<15 passage) previously established from Stage IV melan-
oma [33]. Surface CD133 expression was determined by
flow cytometry for 3 out of the 7 cell lines (LM-MEL-15,
LM-MEL-34, and LM-MEL-62). Expression varied from an
average of 3.7 % for LM-MEL-34, to ~11 % for LM-MEL-
15 and -62 cells. Quantitative RT-PCR demonstrated that
CD133 transcript correlated with surface CD133 protein,
with LM-MEL-15 and -62 displaying similar levels, and
LM-MEL-34 cells having the lowest proportion (Fig. 1a).
We asked whether there was a transcriptional profile
specifically associated with CD133+ melanoma cells. A
larger panel of 7 LM-MEL human primary malignant
melanoma cell lines, including −15, −34 and −62 were
sorted into CD133+ and CD133- populations by
immuno-magnetic cell sorting (MACS), RNA harvested
and the gene expression profile of CD133+ and CD133-
queried by microarray. Data were analyzed via Gene Set
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Enrichment Analysis [36], (Fig. 1b, see Additional file 1:
Table S1 for full list). CD133+ cells could be segregated
from CD133- cells by several pathways. In particular,
CD133+ cells resembled both glioma stem cells and
highly proliferative melanoma cells, and had low
expression of genes associated with a mesenchymal
phenotype, including the epithelial to mesenchymal
transition of breast cancer. CD133- cells had gene
expression resembling invasive, metastatic melanoma,
with increased expression of the epithelial to mesenchy-
mal transition genes. These data indicated clear differ-
ences between CD133+ and CD133- cells.
There are many reports of CD133 as a cancer stem cell
marker, and the GSEA data suggested that CD133+ cells
resembled glioma stem cells. One of the key characteris-
tics of cancer stem cells is self-renewal and asymmetric
division mediated by expression of embryonic stem cell
genes. To determine whether the LM-MEL CD133+ cells
had preferential expression of stem cell genes, expression
of CD133+ and CD133- cells from the 7 LM-MEL cell
lines were compared to gene expression signatures from
~300 human embryonic stem (hES), and inducible pluri-
potent stem cells (iPS) taken from a Gene Expression
Omnibus (GEO). hES and iPS are known to express
CD133 [37]. As a comparison, these profiles were analyzed
against gene expression of fibroblasts and melanocytes
and all microarray data in the GEO database (grey),
(Fig. 1c). As would be expected, hES and iPS gene expres-
sion profiles were the most stem-like, falling at the far left
of the spectrum (black). Expression profiles from fibro-
blasts and melanocytes had much lower representation of
the stem-like metric (blue), consistent with their differen-
tiated state. The gene expression of CD133+ (green) and
CD133- (red) cells was more stem-like than the differenti-
ated melanocytes, consistent with the increased self-
renewal activity and stem cell gene expression observed in
cancer cells. However, the equal distance of CD133+ and
CD133- cells from the hES/iPS stem cell signature implied
that there was no differential stem cell gene expression
between CD133+ and CD133- cells.
Effective depletion of CD133-expressing cells requires
iterative sorting
To identify whether the differential gene expression iden-
tified by GSEA impacted on tumourigenicity of CD133-
and CD133+ cells, LM-MEL-15, -34, and -62 were sorted
into CD133+ and CD133- populations by fluorescent-
activated cell sorting (FACS). FACs sorting was chosen at
this stage, to ensure optimum purity of CD133+ and
CD133- cells for tumourigenic studies. Initial sorting of
LM-MEL-62 cells into CD133+ and CD133- cells and
subsequent culture demonstrated a difference in growth
rate in vitro (Fig. 2a), consistent with the proliferative
signature identified by GSEA.
To accurately sort CD133+ and CD133- cells, only the
highest and lowest 5 % of CD133-stained cells were
rigorously sorted by FACS from LM-MEL-15, -34, and
-62. The initial sort (Sort 1) purified CD133+ cells to a
population >94.3 % CD133+, and CD133- to greater
than 99 % purity, (Fig. 2b, Sort 1 representative, Fig. 2c,
Post-sort 1). After several days in culture to expand the
viable population, surface CD133 was re-measured
(Fig. 2c, Pre-sort 2). Cells with cell surface CD133
dropped to 34.4–55.5 % in the CD133+ population, but
more notably CD133 expression increased in the
CD133- population, to 1.9–8.3 %. This emergence of
CD133+ cells in the CD133- population suggested the
possibility of transient loss of CD133 from the surface of
a CD133+ cell at the time of sorting.
To improve purity, sorting of both populations was
repeated (Fig. 2b, Sort 2 representative), with CD133+
cells re-purified to >95.1 % of cells expressing CD133, and
CD133- with <0.4 % (Fig. 2c, Post-sort 2). Again, cells
were left to recover, then CD133 surface expression re-
measured. A greater proportion of CD133+ cells retained
cell surface CD133 - 52.1–90.0 % (Fig 2c, Pre-sort 3),
while again CD133+ cells in the CD133- population in-
creased to 2.5–7.8 %.
A third sort (Fig. 2b, Sort 3 representative) was then per-
formed to deplete these CD133+ cells from the CD133-
population (Fig. 2c, Post-sort 3). These finally remained
stably depleted of CD133 for 2 weeks in culture (<0.1 %),
(Fig. 2c at 1st injection). As seen previously, CD133+ cells
were purified to >93.5 %, but reverted back to a mixed
population, with 25–35 % of CD133+ cells no longer
displaying CD133 on the cell surface. This iterative sorting
procedure was used to produce highly depleted CD133-
cells, and enriched CD133+ cells, for each experiment.
CD133+ and CD133- cells were equally tumourigenic
We next looked at 2 characteristics often associated with
cancer stem cells in vivo – tumour initiation and tumour
propagation. Highly purified CD133+ and CD133- cells
from LM-MEL-15, -34 and -62, with greater than 95 %
viability, were injected sub-cutaneously into NOD/SCID
mice and allowed to form tumours. Titration of the
starting inoculum of 100,000, 10,000 and 1,000 CD133+
and CD133- cells did not alter tumour initiation, even at
the lowest cell number (Additional file 2: Figure S1).
This suggested there was no loss of tumour-initiating
cells with depletion of CD133.
A serial xeno-transplantation experiment was under-
taken to determine the ability of CD133+ and CD133-
cells to maintain on-going tumour growth. For each
LM-MEL cell line −15, −34 and −62, sub-cutaneous tu-
mours were established in 3 to 5 NOD/SCID mice,
using 105 highly purified, >95 % viable, early passage
CD133+ or CD133- cells. Tumours were allowed to
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grow to ~200 mm3 (Generation 0, or Gen0), then ex-
cised, pooled and a single cell suspension plated to
select the adherent melanoma cells from the host stro-
mal component. These cells were cultured for ~2 weeks
to ensure stability and purity, before surface CD133 ex-
pression was quantified and cells re-injected into mice
(Gen1). No further sorting of CD133+ and CD133- cells
occurred after Gen0 in order to analyze the dynamic
characteristics of the original highly-purified popula-
tions. Both CD133+ and CD133- cells from each LM-
MEL line initiated tumour formation and growth over 7
generations (Gen0 to Gen6), (Fig. 3a). The iterative
Fig. 2 Serial cell sorting is essential to isolate highly pure CD133+ and CD133- populations. a Cell proliferation after seeding 105 LM-MEL-62 CD133- and
CD133+ cells, from an initial FACS sort. Cells stained with crystal-violet after two weeks’ growth. b Serial FACS cell sorting example of CD133+ (green), and
CD133- (red) melanoma cells from primary cell line LM-MEL-34. Sort 1: Sort gates set to collect extreme 5 % of population (Sort 1 Gates), with resulting
sorted populations shown (Post-sort 1 Analysis). Sort 2: Sort 1 cells cultured for ~2 weeks and CD133 expression re-analyzed (Pre-sort 2 Analysis). Cells
re-sorted (Post-sort 2 Analysis). Sort 3: Sort 2 cells cultured and CD133 re-analyzed (Pre-sort 3 Analysis), then re-sorted (Post-sort 3 Analysis). Data
representative of 2 replicate experiments per cell line. c Percentage CD133 surface expression by flow cytometry of CD133+ and CD133- cells from 3
primary cell lines pre- and post- 3 sorts and on day of injection. Data are representative of 2 replicate experiments +/- standard error
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sorting and serial transplantation experiment was re-
peated, and in both independent replicate experiments,
depletion of the CD133+ population did not alter
tumour formation. This demonstrated that there was
no loss of tumour propagation activity with CD133
depletion. Together with the retention of tumour initi-
ation, these data demonstrated there was no cancer
stem cell activity specifically associated with CD133+
cells, consistent with the hES gene signature analysis.
Differences in proliferation rate between CD133+
and CD133- cells were suggested by the gene expres-
sion data, and observed in vitro, so we analysed
growth of CD133+ and CD133- in vivo, using all the
generations of transplanted tumours from all 3 LM-
MEL cell lines.
We analyzed time-to-appearance of palpable tumours
for each sorted population, and while there was a hint
that CD133- tumours appeared more rapidly than
CD133+, this difference was not statistically significant
(data not shown). We also assessed whether there was
a difference in growth rate between CD133- and
CD133+ tumours by analyzing the area under the
growth curve. There was a suggestion that CD133- tu-
mours grew more quickly, but again this was not statis-
tically significant (data not shown). However, there was
a difference in in vitro cell surface expression of
CD133+ and CD133- cells during serial transplant
experiments. Tumour cells were cultured after each
generation and CD133 surface expression measured
prior to reinjection. CD133 expression on CD133- cells
and CD133+ cells were phenotypically distinct, with
CD133- expressing virtually zero CD133 throughout
the 7 generations, as opposed to CD133+ cells that
retained high expression in LM-MEL-15 cells, with
tumours derived from LM-MEL-34 and -62 CD133+
cells showing gradual loss of cell surface CD133 over
time (data representative of 2 replicate experiments,
Fig. 3b).
CD133 could be induced in CD133- tumours in vivo
Due to the phenotypically distinct in vitro CD133
surface expression on CD133- and CD133+ cells be-
tween serial xenotransplantations, we assessed whether
these differences were also evident in vivo. Tumour
sections were stained with CD133 antibody (ahE2) at
Generation 0, 3 and 6. Expression of CD133 was
observed in most tumours throughout the serial xeno-
transplants (Fig. 4a and b). There was particularly high
expression bordering necrotic tissue in some tumours,
consistent with data describing a role for CD133 in
hypoxia and other stress responses [38, 39]. Notably,
both CD133+ and CD133- tumours expressed both cell
surface and intra-cellular CD133 in vivo.
Fig. 3 CD133+ and CD133- cells are equally tumourigenic with distinct phenotypes. a Serial xeno-transplantation of CD133+ and CD133- cells
over 7 generations (Gen0 to Gen6) in NOD/SCID mice. Serially sorted cells from 3 primary cell lines were injected sub-cutaneously (3–5 mice per
group) and tumours grown to ~200 mm3. Tumours were pooled, resuspended and cultured for ~2 weeks before reinjection. Data representative
of 2 replicate experiments. b Flow cytometry of CD133 surface expression of CD133+ and CD133- cells prior to injection into NOD/SCID mice,
over 7 generations (Gen0–Gen6). Data representative of 2 replicate experiments
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CD133- cells derived from CD133+ cells have a CD133+
phenotype
With equal CD133 expression in CD133+ and CD133-
cells in vivo (Fig. 4a and b), yet distinct differences in gene
expression profile (Fig. 1b), and CD133 expression in vitro
(Fig. 3b), we asked whether CD133- cells derived from
CD133+ cells were CD133+ cells that had transiently lost
CD133 from the cell surface or whether they were a
phenotypically distinct population from CD133 + .
LM-MEL-15, -34, -62 CD133+ cells post-Sort 3 were
cultured for several days and cells that lost CD133
expression purified by FACS. These CD133- cells derived
from CD133+ cells (named CD133-(+derived)) were then
xenografted, as were CD133+ and CD133- cells from
Sort 3. Once tumours reached 200 mm3, they were
harvested and CD133 surface expression measured by
flow cytometry immediately ex vivo (Fig. 4a). In all LM-
MEL lines, CD133 expression in the CD133-(+derived) tu-
mours closely reflected the CD133+ tumours and not
the CD133- tumours, suggesting derivation from, and
retention of a CD133+ phenotype. The CD133 transcript
in tumours was quantified by microarray analysis. The
CD133-(+derived) tumours appeared to have consistently
higher CD133+ expression than the CD133- derived
tumours (Fig. 5b). This demonstrated that CD133+ cells
did not give rise to CD133- cells, but merely down-
regulated CD133 from the cell surface.
Cell surface expression of CD133 in the CD133- tu-
mours was not retained in vitro, with CD133 expression
dropping after 24 h in culture (data not shown). This
was unlike the retention of surface CD133 on CD133+
cells in vitro over the same time. This strengthened the
hypothesis that highly purified CD133+ cells were a
population phenotypically distinct from the CD133-
cells, despite the levels of CD133 induced in these cells
by the tumour microenvironment.
Discussion
Following transcriptome analysis of CD133+ and CD133-
cells from a panel of low-passage, primary tumour-derived
melanoma cells, we established that each population had a
distinct gene expression profile in vitro that was conserved
across multiple primary melanoma cell lines. Serial xeno-
graft experiments with 3 different metastatic melanoma
cell lines demonstrated that despite their different gene
profiles, highly purified CD133+ and CD133- populations
were equally tumourigenic with similar proliferation rates.
The equivalent tumourigenicity of these melanoma sub-
sets supports an earlier study that showed both CD133+
and CD133- populations to be equally tumourigenic [8],
but contradicts findings from the same study that result-
ing tumours from both populations contained both
CD133+ and CD133- cells with the same frequency as the
parental tumour. One reason for this discrepancy may lie
in the technical details of isolation of CD133+ and
CD133- populations. We have shown that the initial
CD133- population contained cells that were in fact
CD133+, but had transiently lost CD133 from the
surface at the time of sorting. When isolated, these
CD133-(+derived) cells induced CD133 in vivo exactly
the same as the CD133+ cells, and had the same gene
expression patterns as CD133+ cells, suggesting there
are stable lineages of CD133+ cells in melanoma that
are not interchangeable with CD133- cells.
The impact of this finding was that several rounds of
sorting were essential for isolation of 99.9 % pure and
in-vitro stable CD133- populations. We suggest that
insufficient cell sorting may be partly responsible for the
contradictory evidence of heterogeneity and lineage
reported in melanoma stem cell experiments.
The frequency and equivalent representation of embry-
onic stem cell gene expression, and equivalent tumouri-
genicity of CD133+ and CD133- cells, demonstrated that
in our cells CD133 did not mark a melanoma stem cell.
Consistent with other studies, the actual frequency of the
melanoma-initiating cell was high in each population, at
least 1:1000 and probably higher. NOD/SCID mice were
used throughout our study where engraftment is reduced
compared to NOD/SCID/IL2Rg knock-out (NSG) mice.
Transplantation into NSG mice, which have extreme
defects in both adaptive and innate immunity, indicate
Fig. 4 CD133- derived tumours express CD133 in vivo but cannot
retain it in vitro. a Subcutaneous tumours derived from highly
purified LM-MEL-15 CD133+ (top) and CD133- (bottom) were
formaldehyde-fixed, paraffin-embedded and stained with CD133
antibody (ahE2). Images obtained at 1× magnification (Aperio slide
viewer). b LM-MEL-15, Gen0 CD133 staining (20× magnification) for
CD133+ (left) and CD133- (right) tumours
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that as many as 1:4 human melanoma cells may be cap-
able of engrafting and initiating tumours [8] in this
particular environment. We have not attempted to accur-
ately quantify the tumour-initiating fraction in each
CD133+ and CD133- population, but saw no overt differ-
ence. We also saw no difference in tumour growth. These
data add to the growing body of evidence that the surface
marker CD133 does not label a cancer stem cell/tumour
initiating cell in melanoma, and clearly demonstrates that
both CD133+ and CD133- populations contain cells
capable of initiating and maintaining tumours. This is also
evident in CD133+ cells in the brain tumour glioblastoma
[40, 41], colorectal cancer [32, 42], lung cancer [43], as
well as our data for melanoma.
Our cells were grown in fetal calf serum which could
potentially mask differences in the cancer stem cell
phenotype in CD133+ cells, however, growth of melan-
oma cells in stem cell media leads to the induction of a
neural stem cell phenotype which is inappropriate for
the analysis of melanoma cells [44]. In our study, there
were clear differences observed in vitro between the
CD133+ and CD133- lineages even in the presence of
serum. In vitro, the CD133+ lineage remained function-
ally stable despite changes in expression induced by the
microenvironment, as demonstrated by the ex vivo
expression data. However, the proliferative differences
suggested by GSEA and growth in vitro were obscured
by the variability in CD133+ tumour cells, making none
of the tumour growth data statistically significant.
The normal function of CD133, and its role in can-
cer is still essentially unknown. In glioblastoma, sev-
eral differences have been observed between CD133-
and CD133+ tumours, including proliferation, differ-
entiation and angiogenesis [40, 45–48], with a recent
report that the non-coding miR125b can block migra-
tion of CD133+, but not CD133- cells [49]. Knock-
down of CD133 can delay tumour growth and CD133+
cells promote vasculogenic mimicry [26]. CD133 can be
up-regulated in response to chemotherapy, hypoxia and
other physiological stresses [38, 50–54]. We observed up-
regulation of CD133 in vivo, in both CD133+ and CD133-
melanoma cells. Interestingly we also observed up-
regulation of intracellular CD133, which has recently been
reported in several settings [55, 56]. Again, the function of
intracellular CD133 is not known. While we have not
attempted to identify the signals that led to CD133 up-
regulation, the CD133- cells could not maintain that
expression in vitro, further differentiating them from
CD133+ cells. Whether this difference is only unmasked
in the in vitro system as consistent culturing conditions
may slow down or pause plasticity events, or if it is a
consequence of it, remains to be clarified.
Conclusions
We suggest there are distinct lineages in melanoma
development, based on the phenotype of CD133+ and
CD133- cells. CD133 expression and localisation is
dynamic and driven in part by the cellular micro-
environment, and the CD133+ lineage reported here
does not exhibit continuous localization of CD133 to
the cell surface. Rigorous purification was required to
identify ‘true’ CD133- cells, since CD133+ cells can
transiently downregulate CD133. This highlights the
need to use functional assays, rather than simple
marker expression for phenotypic, and phenotype
switching, analysis [11]. Our data implies that at least
2 phenotypically distinct populations exist within
metastatic melanoma - CD133+ and CD133-, as
Fig. 5 CD133- cells derived from CD133+ cells have a CD133+ phenotype. a Sort 3 CD133+ (green), and CD133- (red) cells were re-sorted and
CD133- cells from the CD133+ population collected (CD133-(+derived), blue). Sub-cutaneous tumours were established from these 3 populations
(2 mice per group) and excised at ~200 mm3. Flow cytometry analysis of CD133 surface expression was performed on viable cells at
2 h post-excision. Signal from isotype control antibody, grey. b CD133+ (green), CD133- (red) and CD133-(+derived) (blue) tumours were
collected and CD133 transcript in each tumour quantified by microarray analysis. Data representative of 2 replicate experiments
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reported in glioblastoma [48]. Within the CD133+
and CD133- populations, environment-driven pheno-
type switching between initiation, proliferation and in-
vasion can occur, but switching between CD133+ and
CD133- lineages does not.
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